Plasminogen concentrate - Kedrion

Drug Profile

Plasminogen concentrate - Kedrion

Alternative Names: Plasminogen - Kedrion

Latest Information Update: 06 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kedrion
  • Class Antithrombotics; Beta-globulins; Blood proteins
  • Mechanism of Action Plasminogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type I plasminogen deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Type I plasminogen deficiency

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Feb 2016 Phase-II/III development is ongoing in Italy and USA
  • 30 Dec 2012 Plasminogen concentrate - Kedrion receives Orphan Drug status for Type I plasminogen deficiency in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top